Press Releases

Date Title and Summary
Toggle Summary Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif. , June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an
Toggle Summary Kezar Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to
Toggle Summary Kezar Provides Data Update from MISSION Study of KZR-616
Two of two patients with Lupus Nephritis saw greater than 50% reduction in proteinuria KZR-616 demonstrates improvement on exploratory efficacy measures across seven measures of disease activity Step-up dosing drives positive safety and tolerability profile SOUTH SAN FRANCISCO, Calif.
Toggle Summary Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO , May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of its executive team will
Toggle Summary Kezar Announces Presentations During Upcoming Scientific Conferences
SOUTH SAN FRANCISCO, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced presentations during
Toggle Summary Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
Noreen R. Henig , MD appointed as Chief Medical Officer Additional data from the ongoing Phase 1b portion of the MISSION study to be presented before the end of Q2 2020 IND submission for KZR-261, a first-in-class protein secretion inhibitor, is on track for Q1 2021 Cash, cash equivalents and
Toggle Summary Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer
SAN FRANCISCO , May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Noreen R.
Toggle Summary Kezar Provides Statement Regarding COVID-19 Pandemic
SOUTH SAN FRANCISCO, Calif. , April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today issued the following statement
Toggle Summary Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressing Additional data from the ongoing Phase 1b portion of the MISSION study to be presented during various medical conferences throughout the course of 2020 KZR-261, a first-in-class protein secretion inhibitor, is currently
Toggle Summary Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its Chief Executive Officer,